Nagoya City University , abbreviated to Meishidai , is a public university in Japan. The main campus is located in Mizuho-ku, Nagoya City. Other three campuses are also located in the city. As of 2011, the university was the highest ranked public university that is not a national university in Japan. Wikipedia.
Japan National Institute of Advanced Industrial Science, Technology, Nagoya City University, National Center For Global Health And Medicine and Sysmex Corporation | Date: 2015-03-11
An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a reagent for quantitative determination of a glycoprotein, which is used for the above measurement methods. Furthermore, an object of the present invention is to provide a glycan-marker glycoprotein as an index for clinical conditions of liver disease, which is capable of identifying the clinical conditions of liver disease depending on the progress of liver disease. The method for measuring a glycoprotein is characterized in that: the glycoprotein is at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject; when the glycoprotein is AGP, AGP binding to a first lectin selected from AOL and MAL is measured; and when the glycoprotein is M2BP, M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII is measured.
TS Technology CO. and Nagoya City University | Date: 2014-10-20
An alertness device includes a heart rate sensor configured to obtain an electrocardiographic signal of a person, a calculation unit configured to calculate the electrocardiographic signal obtained from the heart rate sensor, a waveform generation unit configured to generate an RRI waveform from an electrocardiographic waveform of the electrocardiographic signal, and a determination unit configured to determine the alertness of the person based on the electrocardiographic signal. The calculation unit replicates a same number of RRI waveforms as that of anchors, each anchor being a point where a certain RRI is shorter than an adjacent preceding RRI, moves the time axes of the replicated RRI waveforms such that the anchors of the replicated RRI waveforms are in phase with each other, and calculates a PRSA signal defined as an RRI average for each time axis. The determination unit determines the alertness based on the RRIs and the PRSA signals.
TS Technology Co. and Nagoya City University | Date: 2016-08-31
An alertness device with a high accuracy for determining alertness, a seat equipped with the alertness device, and a method for determining alertness are provided. The alertness device includes: a respiration sensor obtaining respiratory data of a person; a calculation unit calculating the respiratory data, a waveform generation unit generating an RI waveform which is transition in a predetermined time period of a respiratory interval (RI) which is an interval for one respiration; and a determination unit determining a state of alertness of the person on the basis of the respiratory data. The calculation unit calculates an average value of the RI and RrMSSDn in a predetermined time period. In a case where an average value of the subsequent RI is greater than an average value of the RI directly previous to the subsequent RI and in a case where the RrMSSDn of the subsequent RI is greater than a value which is obtained by multiplying the RrMSSDn of the previous RI by a constant , the determination unit determines on the basis of values calculated by the calculation unit that the person is in a state of low alertness.
TS Technology Co. and Nagoya City University | Date: 2016-08-31
Provided are an alertness device configured such that a load is low in the processing for alertness determination and that the accuracy in alertness determination is high, a seat including the alertness device, and an alertness determination method. The alertness device includes a heart rate sensor configured to obtain an electrocardiographic signal of a person, a calculation unit configured to calculate the electrocardiographic signal obtained from the heart rate sensor, a waveform generation unit configured to generate an RRI waveform from an electrocardiographic waveform of the electrocardiographic signal, and a determination unit configured to determine the alertness of the person based on the electrocardiographic signal. The calculation unit replicates the same number of RRI waveforms as that of anchors, each anchor being a point where a certain RRI is shorter than the next preceding RRI. Then, the calculation unit moves the time axes of the replicated RRI waveforms such that the anchors of the replicated RRI waveforms are in phase with each other, and calculates a PRSA signal defined as an RRI average for each time axis. The determination unit determines the alertness of the person based on the RRIs and the PRSA signals.
TS Technology Co. and Nagoya City University | Date: 2015-05-13
Provided is a wakefulness-maintenance apparatus capable of applying a stimulus, which is not perceived to be unpleasant to most seated persons, to a seated person, and effectively maintaining the wakefulness of the seated person. After a control device provided to the wakefulness-maintenance apparatus stimulates the seated person using a first stimulus at a timing close to a human heartbeat, if an index showing the wakefulness of the seated person departs within a predetermined time from a standard indicating that the wakefulness has been maintained, the control device drives a stimulus device to stimulate the seated person using a second stimulus having a timing that differs from the first stimulus.
Japan National Institute of Advanced Industrial Science, Technology, Nagoya City University and National Center For Global Health And Medicine | Date: 2015-12-02
The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic disease including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.
Takase N.,Nagoya City University
Retina | Year: 2015
PURPOSE:: To evaluate the area of the foveal avascular zone (FAZ) detected by en face OCTA (AngioVue, Avanti OCT; Optovue) in healthy and diabetic eyes. METHODS:: Retrospective chart review of patients who underwent fundus examination including en face OCTA. Eyes with proliferative diabetic retinopathy and history of laser photocoagulation were excluded. The FAZ area in the superficial and deep plexus layers were measured and evaluated using ImageJ software. RESULTS:: The FAZ area in the superficial layer was 0.25 ± 0.06 mm in healthy eyes (n = 19), whereas it was 0.37 ± 0.07 mm in diabetic eyes without retinopathy (n = 24) and 0.38 ± 0.11 mm in eyes with diabetic retinopathy (n = 20). Diabetic eyes showed statistically significant FAZ enlargement compared with healthy eyes, regardless of the presence of retinopathy (P < 0.01). The FAZ area in the deep plexus layer was also significantly larger in diabetic eyes than in healthy eyes (P < 0.01). CONCLUSION:: Our data suggest that diabetic eyes show retinal microcirculation impairment in the macula even before retinopathy develops. En face OCTA is a useful noninvasive screening tool for detecting early microcirculatory disturbance in patients with diabetes. © 2015 by Ophthalmic Communications Society, Inc.
Hoshino S.-I.,Nagoya City University
Wiley Interdisciplinary Reviews: RNA | Year: 2012
mRNA decay is intimately linked to and regulated by translation in eukaryotes. However, it has remained unclear exactly how mRNA decay is linked to translation. Progress has been made in recent years in understanding the molecular mechanisms of the link between translation and mRNA decay. It has become clear that the eRF3 family of GTP-binding proteins acts as signal transducers that couple translation to mRNA decay and plays pivotal roles in the regulation of gene expression and mRNA quality control. During translation, the translation termination factor eRF3 in complex with eRF1 recognizes the termination codon which appears at the A site of the terminating ribosome. Depending on whether the termination codon is normal (bona fide) or aberrant (premature), deadenylation-dependent decay or nonsense-mediated mRNA decay (NMD) occurs. mRNA without termination codons and mRNA with the propensity to cause the ribosome to stall are recognized as aberrant by other members of the eRF3 family during translation, and these translational events cause nonstop mRNA decay (NSD) and no-go decay (NGD), respectively. In this review, we focus on how mRNA decay is triggered by translational events and summarize the initiation mechanism for the decay of both normal and aberrant mRNAs. © 2012 John Wiley & Sons, Ltd.
Kondo Y.,Nagoya City University
Journal of Biochemistry | Year: 2014
It is widely accepted that epigenetic alterations are associated with different stages of tumour formation and progression in many cancers. Therefore, epigenetic abnormalities in cancers are emerging as important biomarkers and may have therapeutic potential. The polycomb repressive complex 2 (PRC2) is a key epigenetic regulator that catalyses trimethylation of lysine 27 on histone H3 (H3K27me3) via the histone methyltransferase, EZH2, which confers stemness and regulates differentiation during embryonic development. Given these roles of EZH2 and H3K27me3, plastic and dynamic features of cancer cells, especially cancer stem cells (CSCs), may be closely associated with this epigenetic mechanism. In addition, recent sequencing technology revealed that there are many recurrent mutations in polycomb-related genes, including EZH2, in different types of cancers. Therefore, researchers focused on targeting EZH2 as a novel cancer treatment and identified small compounds that inhibit EZH2 activity. Some of them are now under clinical trial in B-cell lymphoma. However, the underlying mechanisms by which PRC2 precisely regulate epigenetic alterations at certain genomic loci under different cellular conditions remain unclear. In this review, I focus on the recent advancements in EZH2 research, especially its dynamic regulation of epigenetic alterations in tumour cells, including the CSC population, and discuss perspectives and challenges for cancer treatment in the near future. © The Authors 2014. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved.
Masaoka A.,Nagoya City University
Journal of Thoracic Oncology | Year: 2010
Introduction: Thirty years have gone by since the Masaoka staging system of thymoma was proposed in 1981. Although the Masaoka staging system has been accepted by many surgeons and pathologists, some proposals of revision and improvements have been suggested. At this time, I reinvestigated the Masaoka staging system based on the recent follow-up study of the thymomas resected at Nagoya City University. Methods: Using the follow-up results of 211 thymomas in Nagoya, I analyzed the following aspects: (1) evaluation of the Masaoka staging system as a prognostic factor in the Nagoya series and (2) critical assessment of the proposals of revision to the Masaoka staging system. Results: (1) Univariate analysis showed that Masaoka stages were significantly prognostic for overall survival (p < 0.0001). (2) The difference of survivals between stage I and II was not significant, but progression-free survival of stage I was 100% for up to 20 years, whereas one tumor death case in stage II was found. (3) Differences of survival between the cases with and without great vessel invasion in stage III were not significant. (4) Prognosis of N tumors was yet better defined. CONCLUSION: (1) The Masaoka staging system remains a valuable prognostic factor. (2) Combination of stage I with II and separation of stage III into subgroups are not recommended. (3) At the moment, it is better to include N + tumors in stage IVb. © 2010 by the International Association for the Study of Lung Cancer.